Biocryst Pharmaceuticals (BCRX) Operating Leases (2020 - 2026)

Biocryst Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $13.0 million for Q1 2026.

• Quarterly Operating Leases rose 46.67% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.0 million (up 46.67% YoY) and the FY2025 annual result came in at $8.6 million, down 3.27% from the prior year.
• Operating Leases was $13.0 million for Q1 2026 at Biocryst Pharmaceuticals, up from $8.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $13.0 million in Q1 2026 and bottomed at $5.5 million in Q4 2022.
• A 5-year average of $8.5 million and a median of $8.6 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases decreased 28.76% — and 2023, when it surged 51.36%.
• Biocryst Pharmaceuticals' Operating Leases stood at $5.5 million in 2022, then jumped by 51.36% to $8.4 million in 2023, then climbed by 5.61% to $8.9 million in 2024, then dropped by 3.27% to $8.6 million in 2025, then surged by 51.44% to $13.0 million in 2026.
• Business Quant data shows BCRX's Operating Leases at $13.0 million in Q1 2026, $8.6 million in Q4 2025, and $8.8 million in Q3 2025.